ATE255908T1 - Immunotoxinmischungen zur behandlung von immunkrankheiten. - Google Patents

Immunotoxinmischungen zur behandlung von immunkrankheiten.

Info

Publication number
ATE255908T1
ATE255908T1 AT99910879T AT99910879T ATE255908T1 AT E255908 T1 ATE255908 T1 AT E255908T1 AT 99910879 T AT99910879 T AT 99910879T AT 99910879 T AT99910879 T AT 99910879T AT E255908 T1 ATE255908 T1 AT E255908T1
Authority
AT
Austria
Prior art keywords
immunotoxin
mixtures
treatment
immune diseases
provides
Prior art date
Application number
AT99910879T
Other languages
English (en)
Inventor
Oosterhout Ypke Vincentius Van
Emst Janny Elisabeth Van
Original Assignee
Immunotoko B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunotoko B V filed Critical Immunotoko B V
Application granted granted Critical
Publication of ATE255908T1 publication Critical patent/ATE255908T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817Toxins
    • A61K47/6819Plant toxins
    • A61K47/6825Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827Ricin A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT99910879T 1998-03-23 1999-03-19 Immunotoxinmischungen zur behandlung von immunkrankheiten. ATE255908T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7908698P 1998-03-23 1998-03-23
EP98200917A EP0945139A1 (de) 1998-03-23 1998-03-23 Verfahren un Mitteln zur Herstellung von Immunkrankheiten wie Graft-Versus-Host-Krankheit
PCT/NL1999/000156 WO1999048534A1 (en) 1998-03-23 1999-03-19 Methods and means for the treatment of immune related diseases

Publications (1)

Publication Number Publication Date
ATE255908T1 true ATE255908T1 (de) 2003-12-15

Family

ID=8233504

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99910879T ATE255908T1 (de) 1998-03-23 1999-03-19 Immunotoxinmischungen zur behandlung von immunkrankheiten.

Country Status (8)

Country Link
EP (2) EP0945139A1 (de)
AT (1) ATE255908T1 (de)
AU (1) AU2964099A (de)
CA (1) CA2325439A1 (de)
DE (1) DE69913508T2 (de)
ES (1) ES2213355T3 (de)
NZ (1) NZ507171A (de)
WO (1) WO1999048534A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
GB201717966D0 (en) 2017-10-31 2017-12-13 Xenikos Bv Immunotoxins, formulations thereof and their use in medicine
AU2024282452A1 (en) 2023-05-30 2025-11-27 Philikos B.V. Methods and means for the treatment of chronic inflammatory and autoimmune disease
WO2025202213A1 (en) 2024-03-26 2025-10-02 Institut National de la Santé et de la Recherche Médicale Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0407399A4 (en) * 1988-02-03 1991-06-19 Xoma Corporation Immunosupression with anti-pan t-cell immunotoxin compositions
FI105320B (fi) * 1988-04-04 2000-07-31 Oncogen Menetelmä vasta-aineheterokonjugaattien valmistamiseksi, joita käytetään imusoluaktiivisuuden säätelyssä ja diagnoosissa
US5045451A (en) * 1988-10-26 1991-09-03 Board Of Regents Methods for screening antibodies for use as immunotoxins

Also Published As

Publication number Publication date
NZ507171A (en) 2002-06-28
CA2325439A1 (en) 1999-09-30
EP1066058B1 (de) 2003-12-10
WO1999048534A1 (en) 1999-09-30
DE69913508T2 (de) 2004-09-23
ES2213355T3 (es) 2004-08-16
DE69913508D1 (de) 2004-01-22
AU2964099A (en) 1999-10-18
EP1066058A1 (de) 2001-01-10
EP0945139A1 (de) 1999-09-29

Similar Documents

Publication Publication Date Title
NO20026264D0 (no) Fremgangsmåter for behandling av reumatoid artritt ved anvendelse av opplöselig mutant CTLA4 molekyl
GB9009548D0 (en) Chimeric antibody and method
DK1212422T3 (da) Humane CTLA-4-antistoffer og anvendelserne deraf
ATE440618T1 (de) Kombination von cpg und antikírpern gegen cd19, cd20,cd22 oder cd40 zur prävention oder behandlung von krebs.
DE69638269D1 (de) Hochaffine humane antikörper gegen tumorantigene
DK1157042T3 (da) Fremstilling af tetravalente antistoffer
DE69132098D1 (de) Verfahren zur amplifikation von nukleinsäuren
MA27139A1 (fr) Anticorps au cd40.
DE69939058D1 (de) Vorrichtung zur behandlung von peripheren gefässerkrankungen
DE59915227D1 (de) Verfahren zur Behandlung von biologischen Abfällen
DE69522019D1 (de) Einteilige Vorrichtung zur Aufbereitung von biologischen Proben
ATE139562T1 (de) Modifiziertes biologisches material
ATE228765T1 (de) Zusammensetzung und verfahren zur behandlung von pflanzen mit exogenen chemikalien
ATE255908T1 (de) Immunotoxinmischungen zur behandlung von immunkrankheiten.
NO178186C (no) Forbindelser som kan koble metallioner til biologisk nyttige molekyler
ATE257708T1 (de) Kombinationen enthaltend vx478, zidovudin und 3tc zur behandlung von hiv
ATE495193T1 (de) Bag3-antikörper zur nutzung in forschung, diagnose und der behandlung von krankheiten, an denen zelltod beteiligt ist
ATE352563T1 (de) Transplantatabstossung und damit verbundene zustände
ATE209914T1 (de) Verwendung von pyridylmethylsulfinyl-1h- benzimidazol derivaten zur behandlung durch helicobacter verursachter erkrankungen
ATE288498T1 (de) Methoden zur inhibierung von helicobacter pylori
DE60231971D1 (de) Ndet, und seine verwendung zur behandlung von krebs
ATE66340T1 (de) Verfahren zur foerderung von wachstum und gesundheit von nutzpflanzen.
IL125852A0 (en) New pesticide
ATE501760T1 (de) E5564 zur verwendung in der behandlung von allograft-abstossung oder host-versus-graft- erkrankungen
DE69112718D1 (de) Verfahren und Zusammensetzung zur Behandlung von tierischen Exkrementen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties